Dr Sikov on the Benefit of CDK4/6 Inhibitors in HR+/HER2-Neg

William M. Sikov, MD, discusses the benefit of CDK4/6 inhibitors in the treatment of hormone receptor–positive/HER2-negative breast cancers.

Related Keywords

Rhode Island , United States , Williamm Sikov , , Lifespan Cancer Institute , Lifespan Educational Advisory Committee , Infants Hospital , Onclive Tv , Breast Cancer , Cdk4 6 Inhibitors , Her2 Negative Breast Cancers , Hr Positive Breast Cancer ,